Based upon the results of our previous structure activity relationship studies, we have developed a hypothesis to explain the interaction of DAergic agonist and antagonist drugs with DAergic receptors. We have consistently found that permanently charged dopamine agonist and antagonist molecules, while capable of binding to dopamine receptors, have a lower affinity for D2 and D1 dopamine receptors than parent amines which can exist in both protonated (charged) and unprotonated (uncharged) forms at physiological pH. To explain these differences in potency, we propose that: DAergic agonist and antagonists bind to a carboxylate site on the receptor. Thus, the permanently charged analogs would bind to this anionic site. However, the parent agonist and antagonist amines in the protonated form can bind to the receptor in an additional manner: by hydrogen bonding. This hydrogen bonding would reinforce the ionic bond resulting in a stronger bond between the receptor and the drug than the ionic bond alone. We propose to test this hypothesis with the following studies. 1.To calculate the interaction energies between various DAergic agonist and antagonist fragments and a carboxylate group (representing the receptor fragment) and to determine possible relationships between the calculated interaction energies and biological effects of DAergic drugs. 2.To synthesize and study permanently charged analogs of 3-(3-hydroxyphenyl)-N-n-propylpyridine (3-PPP). It has been postulated that the hydrogen on the amine group of 3-PPP is critical for determining activity at the dopamine receptor. 3.To synthesize and study hydrazinium (Aza) analogs of DAergic agonist and antagonist molecules that contain both a permanent positively charged group and a group that can act as a hydrogen bond donor. 4.To synthesize a set of formamidino, guanidino and thiourea analogs of DA, in order to investigate the overall importance of hydrogen bonding in the interaction of DAergic drugs with DAergic receptors.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS017907-09
Application #
3397921
Study Section
Bio-Organic and Natural Products Chemistry Study Section (BNP)
Project Start
1981-12-01
Project End
1992-09-30
Budget Start
1992-04-01
Budget End
1992-09-30
Support Year
9
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
Schools of Pharmacy
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Farooqui, T; Brooks, K; Harrold, M W et al. (1994) Interaction of permanently charged metoclopramide analogs with D-2 dopamine receptors. Gen Pharmacol 25:1577-84
Farooqui, T; Markovich, K; Wallace, L et al. (1993) Interaction of AZA analogs of chlorpromazine with the dopamine D2 receptor. Gen Pharmacol 24:147-51
Harrold, M W; Sriburi, A; Matsumoto, K et al. (1993) The interaction of ammonium, sulfonium, and sulfide analogues of metoclopramide with the dopamine D2 receptor. J Med Chem 36:3166-70
Willins, D L; Wallace, L J; Miller, D D et al. (1992) alpha-Amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonists in the nucleus accumbens and ventral pallidum decrease the hypermotility response to psychostimulant drugs. J Pharmacol Exp Ther 260:1145-51
Harrold, M W; Wallace, R A; Farooqui, T et al. (1989) Synthesis and D2 dopaminergic activity of pyrrolidinium, tetrahydrothiophenium, and tetrahydrothiophene analogues of sulpiride. J Med Chem 32:874-80
Wallace, R A; Farooqui, T; Wallace, L et al. (1988) Interaction of permanently uncharged dopamine analogs with the D-2 dopaminergic receptor. Biochem Pharmacol 37:2077-84
Ross, P C; Burkman, A M (1988) Inhibition of prolactin release from anterior pituitary lactotrophs in culture by sulfur-containing analogs of dopamine. Proc Soc Exp Biol Med 188:87-91
Chang, Y A; Ares, J; Anderson, K et al. (1987) Dopamine agonists: effects of charged and uncharged analogues of dopamine. J Med Chem 30:214-8
Harrold, M W; Chang, Y A; Wallace, R A et al. (1987) Charged analogues of chlorpromazine as dopamine antagonists. J Med Chem 30:1631-5
Sabol, B; Boldry, R; Farooqui, T et al. (1987) Effect of permanently charged and uncharged dopaminergic agonists on the potassium-induced release of [3H]acetylcholine from striatal slices. Biochem Pharmacol 36:1679-85

Showing the most recent 10 out of 12 publications